Anne M. Exall - Concepedia

Author

Anne M. Exall

GlaxoSmithKline (United Kingdom)

Also Known As

A. M. EXALL, Anne Exall, Anne M Exall, Anne M. Exall, Exall, A.M.

Publications

985

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (United Kingdom)GlaxoSmithKline (United States)GlaxoSmithKline (Germany)Molecular Discovery (United Kingdom)

About

Anne M. Exall is an author at GlaxoSmithKline (United Kingdom) specializing in natural sciences, biochemistry, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Natural Sciences	14	15	627
2	Biochemistry	13	13	579
3	Medicine	10	10	475
4	Engineering	7	7	191
5	Biomolecular Engineering	5	5	134

Anne M. Exall

Publications

968

Citations

H-Index

Page 1

	Year	Citations
The discovery of GSK221149A: A potent and selective oxytocin antagonist John Liddle, Michael Allen, Alan D. Borthwick, Bioorganic & Medicinal Chemistry Letters Selective OxytocinMedicinal ChemistryBiochemistryG Protein-coupled ReceptorMedicine	2007	90
Pyridyl-2,5-Diketopiperazines as Potent, Selective, and Orally Bioavailable Oxytocin Antagonists: Synthesis, Pharmacokinetics, and In Vivo Potency Alan D. Borthwick, John Liddle, Dave E. Davies, Journal of Medicinal Chemistry	2012	89
Design and Synthesis of Pyrrolidine-5,5-<i>trans-</i>lactams (5-Oxohexahydropyrrolo[3,2-<i>b</i>]pyrroles) as Novel Mechanism-Based Inhibitors of Human Cytomegalovirus Protease. 2. Potency and Chirality Alan D. Borthwick, Andrew J. Crame, Peter Ertl, Journal of Medicinal Chemistry Hcmv Deltaala ProteaseBioorganic ChemistryNovel Mechanism-based InhibitorsAntiviral DrugChemical Biology	2001	72
Design and Synthesis of Pyrrolidine-5,5‘-<i>trans-</i>Lactams (5-Oxo-hexahydropyrrolo[3,2-<i>b</i>]pyrroles) as Novel Mechanism-Based Inhibitors of Human Cytomegalovirus Protease. 4. Antiviral Activity and Plasma Stability Alan D. Borthwick, Dave E. Davies, Peter Ertl, Journal of Medicinal Chemistry	2003	71
2,5-Diketopiperazines as potent and selective oxytocin antagonists 1: identification, stereochemistry and initial SAR Paul G. Wyatt, Michael Allen, Alan D. Borthwick, Bioorganic & Medicinal Chemistry Letters Selective OxytocinMedicinal ChemistryDrug TargetBiochemistryInitial Sar	2005	66
Synthesis and enzymatic resolution of carbocyclic 2′-ara-fluoro-guanosine: a potent new anti-herpetic agent Alan D. Borthwick, Suzanne Butt, Keith Biggadike, Journal of the Chemical Society Chemical Communications Bioorganic ChemistrySynthetic VirologyAntiviral DrugPharmaceutical ChemistryCorresponding Furanose Compound	1988	58
Fluoro carbocyclic nucleosides: synthesis and antiviral activity of 2'- and 6'-fluoro carbocyclic pyrimidine nucleosides including carbocyclic 1-(2-deoxy-2-fluoro-.beta.-D-arabinofuranosyl)-5-methyluracil and carbocyclic 1-(2-deoxy-2-fluoro-.beta.-D-arabinofuranosyl)-5-iodouracil Alan D. Borthwick, Derek N. Evans, Barrie E. Kirk, Journal of Medicinal Chemistry Medicinal ChemistryPharmaceutical ChemistryBioorganic ChemistryKetone 23Biochemistry	1990	57
2,5-Diketopiperazines as Potent, Selective, and Orally Bioavailable Oxytocin Antagonists. 2. Synthesis, Chirality, and Pharmacokinetics Alan D. Borthwick, Dave E. Davies, Anne M. Exall, Journal of Medicinal Chemistry Molecular PharmacologyMedicinal ChemistryShort Stereoselective SynthesisPharmaceutical SciencePharmacological Study	2005	53
Fluorocarbocyclic nucleosides: synthesis and antiviral activity of 2'- and 6'-fluorocarbocyclic 2'-deoxyguanosines Alan D. Borthwick, Barrie E. Kirk, Keith Biggadike, Journal of Medicinal Chemistry	1991	52
Use of diethylaminosulphur trifluoride (DAST) in the preparation of synthons of carbocyclic nucleosides Keith Biggadike, Alan D. Borthwick, Derek Evans, Journal of the Chemical Society Perkin Transactions 1 HalogenationEngineeringBiochemistryNatural SciencesCarbocyclic Nucleosides	1988	52

Page 1